INCERT
Digital public agency INCERT GIE Luxembourg expands to the private sector with today’s launch of Keys&More, a hardware-agnostic enterprise key management system (KMS) designed for the complex deployment needs of manufacturers and industrial providers.
The KMS solution combines (1) a powerful platform for centralized management, (2) flexible deployment options and (3) strategic consulting services. Available via a cloud-based (KMSaaS), on-premises or hybrid option, Keys&More streamlines management of the entire key lifecycle: key preparation, creation, rotation, disabling, archiving and deletion.
Through one user-friendly platform, original equipment manufacturers (OEMs) oversee user management, digital signatures, encryption, decryption and beyond. This unified system helps them achieve compliance, boost operational efficiency, cut costs and apply cryptography best practices.
As a platform-independent solution, Keys&More functions with any cloud provider and multiple HSM and database vendors.
“Our value lies in our customizable deployment options. We know that the reality of cybersecurity can be messy: It’s common for larger organizations to find themselves with a patchwork of diverse processes and tools,” explains Benoit Poletti, Chief Executive Officer, INCERT. “Our solution turns that patchwork into one cohesive KMS. We adapt to the expertise and systems already present within a company, not the other way around. We’re making responsible key management as painless as possible, while unlocking new strategic opportunities.”
Keys&More expects to resonate with the automotive industry due to its (1) complex deployment needs, (2) growing dependence on connected devices and (3) industry regulations. The solution empowers organizations to safely leverage transformative trends, such as Vehicle-to-Everything, the Internet of Things and production line digitalization.
“This product is the result of INCERT’s historical skillset, our years of collaboration with a major automotive technology provider and our engagement with regulatory committees and R&D projects,” explains Sylvain Arts, Chief Business Officer, INCERT. “We really understand the challenges keeping OEMs from streamlining their key lifecycle management. But new regulations, especially in the automotive industry, mean that the adoption of a cohesive KMS solution cannot wait.”
“There is a strong business case for adopting a centralized KMS solution,” adds Benoit Poletti. “Crisis management, market positioning, compliance and auditing processes all improve with Keys&More. Having an efficient KMS in place makes it easier for organizations to scale, adapt and evolve—including, for example, transitioning to a post-quantum environment.”
“INCERT gave us the best value for money,” recalls INCERT’s major automotive industry client. “We could not live without them […]. Before they were an option, now they are a fundamental piece of the infrastructure. [… They were] very good at getting us everything we needed.”
ABOUT INCERT
INCERT was launched by the Government of Luxembourg in 2012 as a public digital services partner focused on critical IT infrastructure & verification of digital signatures. It soon began consulting foreign governments on the topics of public key infrastructure, identity management, standards & cybersecurity. Offering an entire ecosystem of services & solutions, INCERT’s public & private sector projects span the globe. With over a decade’s worth of insight, INCERT has developed its own unified KMS solution: Keys&More.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412187710/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom